IRWD Ironwood Pharmaceuticals Inc.

+0.18  (+1%)
Previous Close 13.62
Open 13.62
Price To Book -10.87
Market Cap 2134104588
Shares 154,645,260
Volume 571,487
Short Ratio
Av. Daily Volume 1,553,784

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
Olinciguat (IW-1701) - STRONG-SCD
Sickle Cell disease
Approval announced August 21, 2017.
Hyperuricemia associated with gout
Phase 2 data due 2H 2019.
IW-1973 (Praliciguat)
Diabetic nephropathy
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data due mid-2019.
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
Phase 3 data due 2H 2020.
Gastroesophageal reflux disease (GERD)
No additional trials planned.
Phase 2 data due 2H 2019.
IW-1973 (Praliciguat)
Heart failure HFpEF
Phase 2 trial to be initiated 2Q 2019.
Irritable Bowel Syndrome
Phase 1 data due 2H 2019.
Healthy volunteers

Latest News

  1. Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares
  2. Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?
  3. Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
  4. Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
  5. Ironwood Pharmaceuticals to Present at Cowen Health Care Conference
  6. Recent Analysis Shows Yamana Gold, Broadcom Inc., Atlas Air Worldwide, Hawaiian, H&E Equipment Services, and Ironwood Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
  7. Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
  8. Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
  9. Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise
  10. Edited Transcript of IRWD earnings conference call or presentation 13-Feb-19 1:30pm GMT
  11. Why Ironwood's Shares Climbed 11.7% on Wednesday
  12. Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript
  13. Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates
  14. Ironwood: 4Q Earnings Snapshot
  15. Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
  16. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  17. See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
  18. Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline
  19. Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid